<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02864602</url>
  </required_header>
  <id_info>
    <org_study_id>15-5049-A</org_study_id>
    <nct_id>NCT02864602</nct_id>
  </id_info>
  <brief_title>IV Dexamethasone for Prolongation of Peripheral Nerve Block</brief_title>
  <official_title>A Volunteer Study to Determine the Optimal Dose of IV Dexamethasone Required for Prolongation of Peripheral Nerve Block</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a volunteer study examining the effect of different doses of IV dexamethasone on
      prolongation of median nerve block in the forearm.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      18 healthy volunteers aged 18-50 will be recruited (6 patients in each dosing group). Each
      volunteer will receive two forearm median nerve blocks separated by a two week washout
      period. One block will be conducted alongside an infusion of normal saline (control). The
      other block will be conducted alongside a randomised dose of IV dexamethasone (2, 4 or 8mg).
      The order of these interventions will be random. Blocks will be assessed quantitatively with
      cold and sharp sensation, electrical stimulation, quantitative sensory testing (thermal
      tolerance) and grip strength dynamometry. Measures or sensory and motor block including
      onset, intensity and duration will be compared between dosing groups.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2016</start_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The duration of sensory anesthesia and analgesia following median nerve block</measure>
    <time_frame>This will be assessed for up to 12 hours following block</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The duration of motor block following median nerve block</measure>
    <time_frame>This will be assessed for up to 12 hours following block</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects related to nerve block or IV infusion of dexamethasone</measure>
    <time_frame>Volunteers will be phoned at 24-36 hrs and then 7-10 days to ensure full resolution of the block</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Anesthesia, Conduction</condition>
  <arm_group>
    <arm_group_label>Dexamethasone 2mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The experimental intervention in this arm will be an IV infusion of 2mg of dexamethasone. Volunteers will also have a cross-over placebo comparator (saline infusion).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexamethasone 4mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The experimental intervention in this arm will be an IV infusion of 4mg of dexamethasone. Volunteers will also have a cross-over placebo comparator (saline infusion).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexamethasone 8mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The experimental intervention in this arm will be an IV infusion of 8mg of dexamethasone. Volunteers will also have a cross-over placebo comparator (saline infusion).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV dexamethasone</intervention_name>
    <description>An infusion of IV dexamethasone</description>
    <arm_group_label>Dexamethasone 2mg</arm_group_label>
    <arm_group_label>Dexamethasone 4mg</arm_group_label>
    <arm_group_label>Dexamethasone 8mg</arm_group_label>
    <other_name>Dexamethasone sodium phosphate injection USP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ASA 1 (normal healthy) volunteers.

          -  18 - 50 years of age.

          -  60 - 100kg weight.

          -  English speaking.

          -  Female volunteers of childbearing potential will be required to provide a negative
             pregnancy test before being allowed to participate.

          -  Females of child bearing potential must be willing to use medically acceptable birth
             control methods between study interventions and for a minimum of 2 weeks following the
             second nerve block.

        Exclusion Criteria:

          -  Medical disorders (including bleeding disorders).

          -  Use of systemic steroids within 2 weeks of the study, prescription medications, live
             viral vaccines or any recreational drug use.

          -  Hypersensitivity to bupivacaine, dexamethasone or any component of saline.

          -  Contraindication to regional anesthetic block.

          -  Inability to provide informed consent.

          -  Baseline abnormality of hand sensation or motor function.

          -  Pregnancy / breast feeding.

          -  Individuals with mental health disorders (for example bipolar disorder or depression).

          -  Individuals with cataracts or glaucoma.

          -  Any known contraindication to IV dexamethasone as per the product monograph -
             bacteremia and systemic fungal infections, hypersensitivity to any of the products
             components, gastric and duodenal ulcers, certain viral infections i.e. varicella
             herpes genitalis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Vincent Chan, FRCPC</last_name>
    <phone>(416) 603-5118</phone>
    <email>vincent.chan@uhn.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Toronto Western Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincent Chan, FRCPC</last_name>
      <phone>(416) 603-5118</phone>
      <email>vincent.chan@uhn.ca</email>
    </contact>
    <investigator>
      <last_name>Ki J Chin, FRCPC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anahi Perlas, FRCPC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ahtsham Niazi, FRCPC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Faraj Adballah, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kariem El-Boghdadly, FRCA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anthony Short, FRCA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vincent Chan, FRCPC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 9, 2016</study_first_submitted>
  <study_first_submitted_qc>August 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 12, 2016</study_first_posted>
  <last_update_submitted>August 11, 2016</last_update_submitted>
  <last_update_submitted_qc>August 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Regional anesthesia</keyword>
  <keyword>Adjuvant</keyword>
  <keyword>Dexamethasone</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

